Home › Calculator › REGN Dividend Calculator 2026
REGN Dividend DRIP Calculator 2026
0.54% YieldHealthcareRegeneron Pharmaceuticals, Inc. · NASDAQ
Price: $672.15 · Annual div: $3.64/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When REGN pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your REGN snowball 📈
$10,000 in REGN → $2.50M in 10 years · $4.55/month
About Regeneron Pharmaceuticals, Inc. (REGN) — Dividend Analysis 2026
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Compare REGN with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full REGN DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open REGN position with:
🌍 REGN Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold REGN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.54% | -2.26% | $54 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.46% | -2.34% | $46 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.43% | -2.37% | $43 / yr |
| 🇬🇧 UK ISA | 0% | 0.54% | -2.26% | $54 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.49% | -2.31% | $49 / yr |
| 🇨🇦 TFSA | 0% | 0.54% | -2.26% | $54 / yr |
| 🇨🇦 CA Taxable | 25% | 0.41% | -2.39% | $41 / yr |
| 🇦🇺 Super (pension) | 15% | 0.46% | -2.34% | $46 / yr |
| 🇦🇺 AU Taxable | 30% | 0.38% | -2.42% | $38 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.40% | -2.40% | $40 / yr |
| 🇫🇷 FR Taxable | 30% | 0.38% | -2.42% | $38 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 REGN Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $3.64/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 REGN Dividend Payment Schedule
REGN pays quarterly — 4 times per year. Next ex-div: TBD.
📊 REGN vs Healthcare Benchmarks
How REGN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for REGN sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ REGN Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-07-02 | 200 | $650.15 | $130.0K | ||
| Sale | 2026-05-01 | 5 | $701.76 | $3.5K | ||
| Sale | 2026-05-01 | 15 | $702.46 | $10.5K | ||
| Sale | 2026-05-01 | 24 | $703.46 | $16.9K | ||
| Sale | 2026-05-01 | 15 | $704.28 | $10.6K | ||
| Sale | 2026-05-01 | 14 | $705.56 | $9.9K | ||
| Sale | 2026-05-01 | 7 | $706.74 | $4.9K | ||
| Sale | 2026-05-01 | 4 | $707.40 | $2.8K | ||
| Sale | 2026-05-01 | 6 | $709.45 | $4.3K | ||
| Sale | 2026-05-01 | 2 | $710.87 | $1.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where REGN earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the REGN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Regeneron Pharmaceuticals, Inc. (REGN) is currently trading at $672.15, 42% below its 52-week high. The current dividend yield is 0.54% based on an annual payout of $3.64 per share.
REGN (Regeneron Pharmaceuticals, Inc.) — 0.54% Dividend Yield Analysis
Regeneron Pharmaceuticals, Inc. (REGN) is a healthcare stock currently trading at $672.15 with a dividend yield of 0.54%. The company pays an annual dividend of $3.64 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.